SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

HYPERION DEFI, INC.
Date: April 23, 2025 · CIK: 0001682639 · Accession: 0000000000-25-004287

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-286617

Date
April 23, 2025
Author
Division of
Form
UPLOAD
Company
HYPERION DEFI, INC.

Letter

Re: Eyenovia, Inc. Registration Statement on Form S-3 Filed April 18, 2025 File No. 333-286617 Dear Michael Rowe:

April 23, 2025

Michael Rowe Chief Executive Officer Eyenovia, Inc. 23461 S. Pointe Drive, Suite 390 Laguna Hills, CA 92653

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Tim Buchmiller at 202-551-3635 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Julie M. Plyler, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 April 23, 2025

Michael Rowe
Chief Executive Officer
Eyenovia, Inc.
23461 S. Pointe Drive, Suite 390
Laguna Hills, CA 92653

 Re: Eyenovia, Inc.
 Registration Statement on Form S-3
 Filed April 18, 2025
 File No. 333-286617
Dear Michael Rowe:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Tim Buchmiller at 202-551-3635 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Julie M. Plyler, Esq.
</TEXT>
</DOCUMENT>